Effect of cyclosporin A on protein binding of teniposide in cancer patients

被引:3
|
作者
Toffoli, G
Aita, P
Sorio, R
Corona, G
Bertola, A
Colussi, AM
Robieux, I
Boiocchi, M
机构
[1] Ctr Riferimento Oncol, Div Expt Oncol 1, I-33081 Aviano, PN, Italy
[2] Ctr Riferimento Oncol, Div Med Oncol, I-33081 Aviano, PN, Italy
关键词
cyclosporin; protein binding; teniposide;
D O I
10.1097/00001813-199907000-00001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated the effect of cyclosporin A (CSA) on protein binding of teniposide (VM26) in 16 patients with metastatic renal cell carcinoma receiving i.v. VM26 alone over 24 h (total dose, 200 mg/m(2)) and in association with CSA (5 mg/kg/2 h followed by 30 mg/kg/48 h i.v.). CSA was used in an attempt to overcome multidrug resistance. The unbound fraction (%fu) of VM26 was significantly (p = 0.04) higher in the cycles with CSA (median 0.8; range 0.4-1.9) than in the cycles with VM26 alone (median 0.5; range 0.1-1.6). Both total VM26 area under curve concentration (AUC(0-infinity)) and free VM26 AUC(0-infinity) increased after treatment with CSA, but the median increase in free AUC(0-infinity) was higher (2.7-fold) than total AUC(0-infinity) (1.5-fold) (p = 0.04). Bilirubin was significantly (p < 0.01) increased after CSA but no association was observed between bilirubin level and %fu of VM26. Albumin was in the normal range after both VM26 alone and VM26 plus CSA. The nadir of absolute neutrophil count (ANC) after VM26 plus CSA (median 700/mu l, range 1100-2860/mu l) was lower than after VM26 alone? (median 1900/mu l, range 200-6000/mu l) (p= 0.0007). The median percentage of ANC compared to the pretreatment value (ANC nadir/ANC pretreatment x 100) was 39.0% (range 3.1-98.8%) in the cycles with VM26 alone and 16.9% (range 1.4-97.9%) (p=0.007) after VM26 plus CSA. Percentage change of neutrophils significantly correlated with free AUC(0-infinity) VM26 in the cycles with VM26 alone and VM26 plus CSA (p= 0.04, r=-0.53 and p=0.04, r=-0.52, respectively). Only a trend which failed to reach significance was observed between total AUC(0-infinity) VM26 and percentage change of neutrophils in the cycles with VM26 alone and in association with CSA (p=NS, r=-0.33 and p=0.055, r=-0.49, respectively). In conclusion, patients treated with CSA had higher systemic exposure to unbound VM26. [(C) 1999 Lippincott Williams & Wilkins.].
引用
收藏
页码:511 / 518
页数:8
相关论文
共 50 条
  • [31] DIFFERENTIAL EFFECT OF CANCER ON THE SERUM-PROTEIN BINDING OF MIANSERIN AND IMIPRAMINE
    TORRES, I
    SUAREZ, E
    RODRIGUEZSASIAIN, JM
    AGUIRRE, C
    CALVO, R
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1995, 20 (02) : 107 - 111
  • [32] Effect of cyclosporin A on patients with lupus nephritis: A review of the literature
    Ideura T.
    Hora K.
    Kiyosawa K.
    Clinical and Experimental Nephrology, 2000, 4 (3) : 266 - 270
  • [33] Effect of ganciclovir on pharmacokinetics of cyclosporin A in kidney transplant patients
    Yan, Zhenghua
    Wang, Maoyi
    Dong, Weihua
    Zhongguo Yaoxue Zazhi/Chinese Pharmaceutical Journal, 1999, 34 (01): : 39 - 40
  • [34] ESTROGEN-BINDING PROTEIN IN PLASMA OF BREAST-CANCER PATIENTS
    LAING, L
    SMITH, D
    CALMAN, K
    LEAKE, R
    LANCET, 1976, 2 (7988): : 745 - 745
  • [35] INCREASED PLASMA-PROTEIN BINDING OF IMIPRAMINE IN CANCER-PATIENTS
    SCHULZ, P
    LUTTRELL, S
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1982, 2 (06) : 417 - 420
  • [36] PROTEIN-BINDING OF METHOTREXATE IN NORMAL SUBJECTS AND CANCER-PATIENTS
    PAXTON, JW
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1981, 11 (03): : 345 - 346
  • [37] A MODEL TO ACCOUNT FOR THE VARIATION IN CYCLOSPORIN BINDING TO PLASMA-LIPIDS IN TRANSPLANT PATIENTS
    LEGG, B
    GUPTA, SK
    ROWLAND, M
    THERAPEUTIC DRUG MONITORING, 1988, 10 (01) : 20 - 27
  • [38] RETINOL-BINDING PROTEIN, A VITAMIN-A-TRANSPORTING PROTEIN, IN THE URINE OF CANCER-PATIENTS
    SEON, BK
    FITZPATRICK, JE
    PRESSMAN, D
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 106 - 106
  • [39] In-vivo distribution and erythrocyte binding characteristics of cyclosporin in renal transplant patients
    Kurokawa, N
    Kadobayashi, M
    Yamamoto, K
    Arakawa, Y
    Sawada, M
    Takahara, S
    Okuyama, A
    Yanaihara, C
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1996, 48 (06) : 553 - 559
  • [40] TENIPOSIDE IN ADVANCED BREAST-CANCER - A PHASE-II TRIAL IN PATIENTS WITH NO PRIOR CHEMOTHERAPY
    NIELSEN, D
    BOAS, J
    ENGELHOLM, SA
    HANSEN, OP
    DOMBERNOWSKY, P
    ANNALS OF ONCOLOGY, 1992, 3 (05) : 377 - 378